Merz Laurent, Zimmermann Stefan, Peters Solange, Cavassini Matthias, Darling Katharine E A
Infectious Diseases Service, Department of Medicine, Lausanne University Hospital, Lausanne, Switzerland.
Oncology Centre, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Oncologist. 2016 Oct;21(10):1176-1182. doi: 10.1634/theoncologist.2016-0107. Epub 2016 Jul 20.
Although the prevalence of non-AIDS-defining cancers (non-ADCs) among people living with HIV is rising, we observed HIV testing rates below 5% at our oncology center, against a regional HIV prevalence of 0.2%-0.4%. We performed the Investigating Barriers in HIV-Testing Oncology Patients (IBITOP) study among oncology physicians and patients.
Between July 1 and October 31, 2013, patients of unknown HIV status newly diagnosed with solid-organ non-ADCs referred to Lausanne University Hospital Oncology Service, Switzerland, were offered free HIV testing as part of their oncology work-up. The primary endpoints were (a) physician willingness to offer and patient acceptance of HIV testing and (b) physicians' reasons for not offering testing.
Of 239 patients of unknown HIV status with a new non-ADC diagnosis, 43 (18%) were offered HIV testing, of whom 4 declined (acceptance rate: 39 of 43; 91%). Except for 21 patients tested prior to oncology consultation, 175 patients (of 239; 73%) were not offered testing. Testing rate declined among patients who were >70 years old (12% versus 30%; p = .04); no non-European patients were tested. Physicians gave reasons for not testing in 16% of cases, the main reason being patient follow-up elsewhere (10 patients; 5.7%). HIV testing during the IBITOP study increased the HIV testing rate to 18%.
Although the IBITOP study increased HIV testing rates, most patients were not tested. Testing was low or nonexistent among individuals at risk of late HIV presentation (older patients and migrants). Barriers to testing appear to be physician-led, because patient acceptance of testing offered was very high (91%). In November 2013, the Swiss HIV testing recommendations were updated to propose testing in cancer patients. Phase II of the IBITOP study is examining the effect of these recommendations on HIV testing rates and focusing on physician-led testing barriers.
Patients of unknown HIV status newly diagnosed with solid-organ non-AIDS-defining cancers were offered free HIV testing. Physician and patient barriers to HIV testing were examined. Most patients (82%) were not offered testing, and testing of individuals at risk of late HIV presentation (older patients and migrants) was low or nonexistent. Conversely, patient acceptance of testing offered was very high (91%), suggesting that testing barriers in this setting are physician-led. Since this study, the Swiss HIV testing recommendations now advise testing cancer patients before chemotherapy. Phase II of the Investigating Barriers in HIV-Testing Oncology Patients study is examining the effect of these recommendations on testing rates and physician barriers.
尽管艾滋病毒感染者中非艾滋病定义性癌症(非 ADC)的患病率在上升,但我们在肿瘤中心观察到艾滋病毒检测率低于 5%,而该地区艾滋病毒患病率为 0.2%-0.4%。我们在肿瘤内科医生和患者中开展了艾滋病毒检测肿瘤患者障碍调查(IBITOP)研究。
2013 年 7 月 1 日至 10 月 31 日期间,瑞士洛桑大学医院肿瘤服务中心新诊断为实体器官非 ADC 且艾滋病毒感染状况未知的患者,作为肿瘤检查的一部分,可接受免费艾滋病毒检测。主要终点为:(a)医生提供艾滋病毒检测的意愿及患者对检测的接受情况;(b)医生不提供检测的原因。
在 239 名艾滋病毒感染状况未知且新诊断为非 ADC 的患者中,43 名(18%)接受了艾滋病毒检测,其中 4 名拒绝(接受率:43 名中的 39 名;91%)。除 21 名在肿瘤会诊前接受检测的患者外,239 名患者中有 175 名(73%)未接受检测。70 岁以上患者的检测率下降(12%对 30%;p = 0.04);无非欧洲患者接受检测。医生在 16%的病例中给出了不检测的原因,主要原因是患者在其他地方接受随访(10 名患者;5.7%)。IBITOP 研究期间的艾滋病毒检测使艾滋病毒检测率提高到了 18%。
尽管 IBITOP 研究提高了艾滋病毒检测率,但大多数患者未接受检测。在有晚期艾滋病毒感染风险的个体(老年患者和移民)中,检测率较低或未进行检测。检测障碍似乎由医生主导,因为患者对提供的检测接受度非常高(91%)。2013 年 11 月,瑞士艾滋病毒检测建议更新,提议对癌症患者进行检测。IBITOP 研究的第二阶段正在研究这些建议对艾滋病毒检测率的影响,并关注由医生主导的检测障碍。
新诊断为实体器官非艾滋病定义性癌症且艾滋病毒感染状况未知的患者可接受免费艾滋病毒检测。研究了医生和患者在艾滋病毒检测方面的障碍。大多数患者(82%)未接受检测,有晚期艾滋病毒感染风险的个体(老年患者和移民)的检测率较低或未进行检测。相反,患者对提供的检测接受度非常高(91%),表明这种情况下的检测障碍由医生主导。自本研究以来,瑞士艾滋病毒检测建议现建议在化疗前对癌症患者进行检测。艾滋病毒检测肿瘤患者障碍调查研究的第二阶段正在研究这些建议对检测率和医生障碍的影响。